Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Tumoral Injections of Ex Vivo Expanded Natural Killer Cells in Recurrent or Progressive Malignant Brain Tumors
NCT05887882Phase 1Suspended
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of transforming growth factor-beta-imprinted natural killer cells in brain tumor (3 arms). Primary endpoints: Proportion of participants with treatment-emergent adverse events at 1 year and Recommended Phase II dose at 1 year. Started May 2024; status: suspended.
02
Drugs
transforming growth factor-beta-imprinted natural killer cells
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT05887882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887882.